CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products

Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cell has changed the treatment landscape of B-cell non-Hodgkin’s lymphoma (NHL), especially for aggressive B-cell lymphomas. Single-center and multicenter clinical trials with anti-CD19 CAR T-cell therapy have shown great activit...

Descripción completa

Detalles Bibliográficos
Autores principales: Chavez, Julio C., Bachmeier, Christina, Kharfan-Dabaja, Mohamed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466472/
https://www.ncbi.nlm.nih.gov/pubmed/31019670
http://dx.doi.org/10.1177/2040620719841581

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466472/
https://www.ncbi.nlm.nih.gov/pubmed/31019670
http://dx.doi.org/10.1177/2040620719841581

Ejemplares similares